| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |